-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Verve Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2022 to Q4 2024.
- Verve Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending December 31, 2024 was $73K, a 128% increase year-over-year.
- Verve Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending December 31, 2024 was $349K, a 26.9% increase year-over-year.
- Verve Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2024 was $349K, a 26.9% increase from 2023.
- Verve Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $275K, a 419% increase from 2022.
- Verve Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $53K.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)